- Global Pharma News & Resources

Aurora Kinase B - Pipeline Review, H2 2018 -

The "Aurora Kinase B - Pipeline Review, H2 2018" drug pipelines has been added to's offering.

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.


  • The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B
  • The report reviews Aurora Kinase B targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aurora Kinase B targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aurora Kinase B targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aurora Kinase B targeted therapeutics

Companies Featured

  • AbbVie Inc
  • Advenchen Laboratories LLC
  • Aeterna Zentaris Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Chipscreen Biosciences Ltd
  • Cielo Therapeutics Inc
  • Merck & Co Inc
  • Sanofi
  • Sareum Holdings Plc

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018